Pfizer (NYSE:PFE) Issues FY 2026 Earnings Guidance
by Amy Steele · The Cerbat GemPfizer (NYSE:PFE – Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.800-3.000 for the period, compared to the consensus EPS estimate of 2.970. The company issued revenue guidance of $59.5 billion-$62.5 billion, compared to the consensus revenue estimate of $61.3 billion.
Pfizer Price Performance
PFE traded down $0.05 on Thursday, reaching $26.48. The company had a trading volume of 48,234,310 shares, compared to its average volume of 42,965,777. The business has a 50 day simple moving average of $27.16 and a 200 day simple moving average of $26.14. The company has a market cap of $150.56 billion, a price-to-earnings ratio of 20.21 and a beta of 0.35. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer has a 52-week low of $21.97 and a 52-week high of $28.75.
Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.48%. Pfizer’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts anticipate that Pfizer will post 2.97 EPS for the current year.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.
Wall Street Analyst Weigh In
A number of research analysts have commented on the stock. Royal Bank Of Canada reiterated an “underperform” rating and set a $25.00 price target on shares of Pfizer in a research report on Monday, April 20th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research report on Monday, March 2nd. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Citigroup increased their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Finally, HSBC increased their price target on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $28.74.
Key Stories Impacting Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Q1 beat and guidance reaffirmed: Pfizer reported better-than-expected Q1 revenue and EPS and reiterated FY2026 guidance, reinforcing the company’s transition beyond pandemic-driven sales and supporting near-term earnings visibility. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
- Positive Sentiment: Oncology momentum: Recent FDA approval (VEPPANU) and positive Phase 3 data (ELREXFIO) bolster Pfizer’s oncology franchise, which is a key driver of longer-term growth and valuation upside. Pfizer Oncology Advances Raise New Questions For Valuation And Momentum
- Positive Sentiment: Dividend credibility restored: Coverage highlighting management’s actions has reduced concerns about Pfizer being a yield trap, supporting investor confidence in the roughly 6.5% yield. Pfizer’s 6.5% Dividend Yield Looked Too Good to Be True — but Management Just Silenced the Skeptics
- Positive Sentiment: Unusual call buying: Large intraday options activity — ~254,818 calls (≈84% above normal daily call volume) — signals some traders are taking bullish, leveraged positions that could amplify upside moves if news flows remain positive.
- Neutral Sentiment: Lyme vaccine dosing trial update: A new fifth‑dose VLA15 trial was announced; it signals ongoing R&D optimization but outcome/timing uncertainty limits immediate stock impact. Pfizer’s Next Lyme Shot: What a Fifth-Dose VLA15 Trial Signals for PFE Investors
- Neutral Sentiment: Mixed analyst views and valuation debate: Analysts differ on PFE’s forward momentum and valuation after Q1 — that keeps sentiment mixed and may limit large directional moves until clearer catalysts arrive. Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Compass Therapeutics (CMPX)
- Negative Sentiment: Trial termination trims oncology upside: Pfizer ended a Phase 1b/2 lymphoma combo trial, removing a small piece of future oncology optionality and introducing modest near-term disappointment for pipeline bulls. Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. Darwin Wealth Management LLC bought a new stake in Pfizer in the second quarter valued at $32,000. IFC & Insurance Marketing Inc. bought a new stake in Pfizer in the fourth quarter valued at $34,000. Birchwood Financial Partners Inc. bought a new stake in Pfizer in the fourth quarter valued at $38,000. WFA of San Diego LLC bought a new stake in Pfizer in the second quarter valued at $40,000. Finally, Atlas Capital Advisors Inc. bought a new stake in Pfizer in the fourth quarter valued at $41,000. Institutional investors own 68.36% of the company’s stock.
About Pfizer
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.